Sendai, Japan

Kunio Ogasawara


Average Co-Inventor Count = 2.0

ph-index = 3

Forward Citations = 29(Granted Patents)


Location History:

  • Miyagiken, JP (1998)
  • Sendai, JP (1991 - 2006)

Company Filing History:


Years Active: 1991-2006

Loading Chart...
30 patents (USPTO):Explore Patents

Title: **Kunio Ogasawara: Innovator in Antitumor Compound Synthesis**

Introduction

Kunio Ogasawara, based in Sendai, Japan, is a notable inventor with an impressive portfolio of 30 patents. His work primarily focuses on synthesizing compounds with potential antitumor activity, contributing significantly to the field of medicinal chemistry.

Latest Patents

Among his latest innovations, Ogasawara has developed intermediates and improved processes for the preparation of neplanocin A. This includes intermediate compounds such as 2-(t-butyldimethylsilyloxymethyl)-3,4-[(dimethylmethylene)dioxy]-5-hydroxy-tricyclo[5.2.1.0]dec-8-ene, which are crucial for synthesizing neplanocin A, known for its strong antitumor activity. Additionally, he has enhanced processes starting from optically active 2-hydroxymethyl-5-hydroxy-tricyclo[5.2.1.0]deca-3,8-diene, incorporating a key retro-Diels-Alder reaction step to optimize the synthesis.

Career Highlights

Ogasawara's professional journey includes significant tenure at notable companies such as Chisso Corporation and Asahi Denka Kogyo K.K. His contributions at these organizations have paved the way for advancements in chemical processes and compound developments related to cancer research.

Collaborations

Throughout his career, Ogasawara has worked alongside esteemed coworkers, including Seiichi Takano and Naoyuki Yoshida. These collaborations have fostered innovative research and developments in their respective fields, enhancing the impact of their combined expertise.

Conclusion

Kunio Ogasawara stands out as a prolific inventor whose work in the preparation of neplanocin A and other compounds has great potential for medicinal applications. His dedication and innovative spirit continue to influence advancements in medicinal chemistry and antitumor therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…